Last reviewed · How we verify

Ketamina-Propofol Combination

Universidad de Cartagena · FDA-approved active Small molecule

Ketamina-Propofol Combination is a Anesthetic combination Small molecule drug developed by Universidad de Cartagena. It is currently FDA-approved for Induction and maintenance of general anesthesia, Procedural sedation. Also known as: Ketofol.

A combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid anesthesia and sedation through dual CNS depression pathways.

A combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid anesthesia and sedation through dual CNS depression pathways. Used for Induction and maintenance of general anesthesia, Procedural sedation.

At a glance

Generic nameKetamina-Propofol Combination
Also known asKetofol
SponsorUniversidad de Cartagena
Drug classAnesthetic combination
TargetNMDA receptor (ketamine); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Ketamine blocks N-methyl-D-aspartate (NMDA) glutamate receptors to provide dissociative anesthesia and analgesia, while propofol enhances GABAergic inhibitory neurotransmission to produce sedation and hypnosis. The combination leverages synergistic effects to achieve faster induction, reduced dosing requirements, and potentially improved hemodynamic stability compared to either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketamina-Propofol Combination

What is Ketamina-Propofol Combination?

Ketamina-Propofol Combination is a Anesthetic combination drug developed by Universidad de Cartagena, indicated for Induction and maintenance of general anesthesia, Procedural sedation.

How does Ketamina-Propofol Combination work?

A combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid anesthesia and sedation through dual CNS depression pathways.

What is Ketamina-Propofol Combination used for?

Ketamina-Propofol Combination is indicated for Induction and maintenance of general anesthesia, Procedural sedation.

Who makes Ketamina-Propofol Combination?

Ketamina-Propofol Combination is developed and marketed by Universidad de Cartagena (see full Universidad de Cartagena pipeline at /company/universidad-de-cartagena).

Is Ketamina-Propofol Combination also known as anything else?

Ketamina-Propofol Combination is also known as Ketofol.

What drug class is Ketamina-Propofol Combination in?

Ketamina-Propofol Combination belongs to the Anesthetic combination class. See all Anesthetic combination drugs at /class/anesthetic-combination.

What development phase is Ketamina-Propofol Combination in?

Ketamina-Propofol Combination is FDA-approved (marketed).

What are the side effects of Ketamina-Propofol Combination?

Common side effects of Ketamina-Propofol Combination include Hypotension, Respiratory depression, Emergence reactions (ketamine-related), Injection site pain (propofol-related), Dissociation.

What does Ketamina-Propofol Combination target?

Ketamina-Propofol Combination targets NMDA receptor (ketamine); GABA-A receptor (propofol) and is a Anesthetic combination.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing